Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tamsulosin - Astellas Pharma

Drug Profile

Tamsulosin - Astellas Pharma

Alternative Names: Alna; Alna OCAS; Amsulosin; Expros; Flomax; Flomax MR; Harnal; Harnal D; Harnalidge D; Josir; Josir LP; Omic; Omix LP; Omnic; Omnic-OCAS; Pradif; Pradif T; Secotex; TOCAS; Urolosin; Urolosin OCAS; WOWTAB®; Y 617; YM 12617; YM 617

Latest Information Update: 14 Jan 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astellas Pharma
  • Developer Astellas Pharma; Boehringer Ingelheim; CSL
  • Class Amines; Phenyl ethers; Small molecules; Sulfonamides
  • Mechanism of Action Alpha-1a adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Benign prostatic hyperplasia
  • Discontinued Neurogenic bladder; Prostatitis; Urinary calculi; Urination disorders

Most Recent Events

  • 30 Mar 2016 Launched for Benign prostatic hyperplasia in Taiwan (PO) before March 2016
  • 01 Aug 2014 Astellas completes a phase I drug interaction study in volunteers in Germany (NCT02169713)
  • 01 May 2014 Astellas Pharma initiates enrolment in a phase I drug interaction study in volunteers in Germany (NCT02169713)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top